In the past 10 years, CFTR-targeted therapies (CFTR modulators) have further improved symptoms and quality of life, demonstrating that addressing the molecular defect in CF is an effective strategy and warrants further research (3). This evidence concerns the gene CFTR and cystic fibrosis.